Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) –modified human GH (MOD-4023) is developed for once-a-week
dosing regimen in GH-deficient (GHD) adults
Kataev, V.A.,
Petrova, S.F.,
Perfilova, V.N.,
Murinov, Y.I.,
Bashkatov, S.A.,
Ivanov, S.P.,
Kataev, V.V.,
Agletdinov, E.F. (2021) a single intragastric administration in various
doses [1680, 3360, and 6720 mg/kg in terms
Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) children with GHD.
Design: Randomized, open-label, active-controlled study of three
doses of weekly Trans
]acetic acid hydrazide (laboratory code M-20). Neuropharmacological analysis showed that M-20 at
doses of 0
on rats by giving them water suspension of ore in a
dose of 600 mg/kg of rats' body weight within two
Tyurin, Anton V.,
Akhiyarova, Karina E.,
Valishin, Damir A.,
Sadretdinova, Lidiya D.,
Khusainova, Leonora N.,
Zagidullin, Naufal S.,
Gantseva, Khalida K.,
Pavlov, Valentin N. (2022) received tocilizumab, baricitinib, high
doses of dexamethasone, or standard therapy. Results
on the development of chronic generalized catarrhal gingivitis, to suggest a treatment
regimen using a complex